Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2125 (LINC02125) is a human long non-coding RNA gene that produces a transcript longer than 200 nucleotides and does not encode a protein[6][1]. Like other lincRNAs, LINC02125 is transcribed from a region of the genome that does not overlap with any protein-coding gene and is classified as a long intergenic non-coding RNA[3]. LincRNAs are known to act as regulators of gene expression through diverse mechanisms including chromatin remodeling, altering genome architecture, stabilizing RNAs, regulating transcription, and interacting with protein complexes[3]. The specific biological function, disease associations, or therapeutic targeting of LINC02125 itself have not been well characterized as of 2025. There are no known drugs that target this RNA directly, and its use as a biomarker or its relevance to specific diseases remains unclear[1][6].
Not applicable (no drugs or established inhibitors/agonists documented)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2125 (LINC02125).